Search clinical trials for: Intraarterial Cetxuimab (Erbitux)

Total 1011 results

Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
ARCAGY/ GINECO GROUP

Terminated

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix (ERBUS)

Cervix Cancer

France
Eli Lilly and Company
Bristol-Myers Squibb

Terminated

A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Ovarian Cancer

United States
Sorlandet Hospital HF
Merck KGaA, Darmstadt, Germany; Frontier Science & Technology Research Foundation...

Completed

Novel Treatment Option for Neuropathic Pain (NoTOPain)

Neuralgia | Complex Regional Pain Syndromes

Norway
Theagenio Cancer Hospital

Unknown

Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck

Head and Neck Neoplasms | AJCC Stage III/IV

Greece
University of Pittsburgh
Bristol-Myers Squibb

Completed

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

Non Small Cell Lung Cancer (NSCLC)

United States
Wuhan Union Hospital, China

Recruiting

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Colorectal Neoplasms Malignant

China
Cascadian Therapeutics Inc.

Completed

Phase 1 and 2 Study of PX-866 and Cetuximab

Incurable Metastatic Colorectal Carcinoma | Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

United States, Canada
St. Luke's-Roosevelt Hospital Center
Bristol-Myers Squibb

Terminated

A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients

Colon Cancer

United States
University of Wisconsin, Madison
National Institute of Dental and Craniofacial Research (NIDCR); American Cancer...

Completed

Cetuximab in Head and Neck Cancer Patients

Head and Neck Cancer | Squamous Cell Carcinoma

United States
University of Zurich

Completed

A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab

Laryngeal Cancer | Hypopharyngeal Cancer | Oropharyngeal Cancer

Switzerland
Curegenix Inc.
Merck Sharp & Dohme LLC

Recruiting

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Solid Tumors | GI Cancer

United States, Taiwan
Masonic Cancer Center, University of Minnesota

Completed

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Lecia V. Sequist
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical... and other collaborators

Terminated

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

Non-small Cell Lung Cancer

United States
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
Azienda USL 4 Prato
Università degli Studi di Brescia

Terminated

Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT)

Head and Neck Neoplasms | Pharyngeal Neoplasms | Mouth Neoplasms | Laryngeal Neoplasms

Italy
Ruijin Hospital
Henan Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaborators

Unknown

Cetuximab Monotherapy Maintenance Treatment in mCRC

Colorectal Cancer
Eli Lilly and Company

Completed

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, United States, Canada
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (BERING-CRC)

Metastatic Colorectal Carcinoma

Austria, Germany
Ruijin Hospital
Xiangya Hospital of Central South University; Chinese PLA General Hospital; West... and other collaborators

Not yet recruiting

Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

Colorectal Cancer
University of Cincinnati

Completed

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
David A. Clump, MD, PhD

Completed

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Intergroupe Francophone de Cancerologie Thoracique

Completed

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Stage III Non-small Cell Lung Cancer

France
National Health Research Institutes, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaborators

Unknown

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

Colorectal Cancer | Drug Resistance | Mass Spectrometry | RAS-RAF Pathway Deregulation

Taiwan
Eli Lilly and Company

Completed

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Rabin Medical Center
Meir Medical Center; Kaplan Medical Center

Unknown

CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT

Squamous Cell Carcinoma

Israel
HiberCell, Inc.

Completed

Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer

Colorectal Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (NEXT)

Non-Small Cell Lung Cancer (NSCLC)

Germany
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Glioma | Melanoma | Thyroid Cancer | Non-Small-Cell Lung Cancer

United States, Canada, Israel
West China Hospital

Recruiting

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

China
Heinrich-Heine University, Duesseldorf

Unknown

Novel Therapy of PAD by Combined Transplantation of BMCs

Peripheral Arterial Disease

Germany
Hadassah Medical Organization
Merck Serono International SA

Terminated

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Cancer of Colon

Israel
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Colorectal Neoplasms

India
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
Nektar Therapeutics

Completed

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Cervical Cancer | Colorectal Cancer | Head and Neck Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
The Methodist Hospital Research Institute
Bristol-Myers Squibb

Completed

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients (ICE)

Breast Cancer

United States
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

China
Washington University School of Medicine

Completed

Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer (SCCHN)

Carcinoma, Squamous Cell

United States
Merck KGaA, Darmstadt, Germany
Choice Pharma Taiwan

Completed

A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

Carcinoma, Squamous Cell of Head and Neck

Taiwan
University of Campania "Luigi Vanvitelli"

Recruiting

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Metastatic Colorectal Cancer

Italy
Washington University School of Medicine
Novartis Pharmaceuticals

Completed

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (HNSCC)

Squamous Cell Carcinoma of the Head and Neck

United States
University of California, Davis
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Shandong Cancer Hospital and Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; RenJi Hospital and other collaborators

Completed

Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma (EXCEL)

Esophageal Cancer

China
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® (GORTEC 2009-01)

Head and Neck Carcinoma

France
Johann Wolfgang Goethe University Hospital

Completed

Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD)

Arterial Occlusive Diseases

Germany
Johann Wolfgang Goethe University Hospital

Completed

Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy

Diabetic Neuropathies

Germany
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia

Search clinical trials for: Intraarterial Cetxuimab (Erbitux)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations